Rocket Pharmaceuticals Inc (RCKT)
7.87
+0.24
(+3.15%)
USD |
NASDAQ |
May 01, 16:00
7.92
+0.05
(+0.64%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 839.18M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -64.54% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.812 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 92.73% |
Profile
Edit
| Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies. |
| URL | https://www.rocketpharma.com |
| Investor Relations URL | https://rocketpharmaceuticals.gcs-web.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 06, 2025 (est.) |
| Last Earnings Release | Feb. 27, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies. |
| URL | https://www.rocketpharma.com |
| Investor Relations URL | https://rocketpharmaceuticals.gcs-web.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 06, 2025 (est.) |
| Last Earnings Release | Feb. 27, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |